Products Affected - Description

• • Bicillin C-R intramuscular suspension for injection, Pfizer, 1,200,000 units (600,000 units penicillin G benzathine/600,000 units penicillin G procaine), 2 mL prefilled syringe, 10 count, NDC 60793-0600-10
  • Bicillin C-R intramuscular suspension for injection, Pfizer, 1,200,000 units (600,000 units penicillin G benzathine/600,000 units penicillin G procaine), 2 mL pediatric prefilled syringe, 10 count, NDC 60793-0601-10
  • Bicillin C-R 900/300 intramuscular suspension for injection, Pfizer, 1,200,000 units (900,000 units penicillin G benzathine/300,000 units penicillin G procaine), 2 mL pediatric prefilled syringe, 10 count, NDC 60793-0602-10

Reason for the Shortage

• • Pfizer has Bicillin-CR on shortage due to increased demand and manufacturing delays. Pfizer is allocating resources towards manufacturing Bicillin-LA due to increased syphilis infection rates. A Dear Healthcare Professional Letter can be found at: https://www.fda.gov/media/169427/download.

Available Products

• • There is insufficient supply for usual ordering

• • Pfizer has Bicillin-CR 1,200,000 units adult 2 mL syringes and 1,200,000 units pediatric 2 mL syringes on back order and the company estimates a release date of June 2025. The Bicillin-CR (900/300) 2 mL syringes are on back order and the company estimates a release date of June 2025.